CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 357 enrolled
Drug / intervention
Sufentanil NanoTab PCA System/15 mcg +1 moredrug
Likely dose
Sufentanil NanoTab PCA System/15 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01539538
NCT01539538Phase 3Completed

A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

Talphera, Inc·interventional·Posted Feb 27, 2012·Updated Oct 1, 2015

In Brief

A Phase 3 clinical trial evaluating Sufentanil NanoTab PCA System/15 mcg and morphine IV PCA for Post-Operative Pain. Completed, enrolled 357 participants across 16 sites.

Detailed Summary

The study is intended to show that the Sufentanil NanoTab PCA System is as effective as morphine intravenous patient-controlled analgesia (IV PCA) for treating pain after surgery. Each patient will use either the Sufentanil NanoTab PCA System or morphine IV PCA to treat their pain for at least 48 hours and up to 72 hours after surgery while in the hospital.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 27, 2012
Enrollment StartApr 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.3 years ago

Interventions

Sufentanil NanoTab PCA System/15 mcgdrug

15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours

morphine IV PCAdrug

1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours